Novartis claims best earnings in years, validating shift to pure-play strategynews2025-01-31T11:40:51+00:00January 31st, 2025|Endpoints News|
Vertex’s non-opioid pain drug Journavx is approved by FDAnews2025-01-30T23:07:12+00:00January 30th, 2025|Endpoints News|
Regeneron wins appeals court orders backing halt on Eylea biosimilarsnews2025-01-30T20:59:52+00:00January 30th, 2025|Endpoints News|
FDA approves Axsome’s acute migraine treatment after 2022 rejectionnews2025-01-30T20:52:30+00:00January 30th, 2025|Endpoints News|
Takeda scraps programs as it raises full-year guidance news2025-01-30T16:24:21+00:00January 30th, 2025|Endpoints News|
Takeda CEO Christophe Weber to retire in June 2026, Julie Kim to take overnews2025-01-30T11:51:08+00:00January 30th, 2025|Endpoints News|
Sanofi is in the market for M&A, thanks to ‘strong’ balance sheetnews2025-01-30T11:40:41+00:00January 30th, 2025|Endpoints News|
Teva CEO says Austedo can grow ‘way beyond’ impact of IRAnews2025-01-29T20:21:03+00:00January 29th, 2025|Endpoints News|
Trump administration makes first comments on how it will run IRA drug negotiationsnews2025-01-29T14:23:28+00:00January 29th, 2025|Endpoints News|
Kennedy hearing updates: Trump HHS nominee faces Senatenews2025-01-29T14:00:00+00:00January 29th, 2025|Endpoints News|
